Clinical trial NCT05869513: Krill Oil and Resistance Exercise in Older Adults
Official title: The Effects of Krill Oil Supplementation on Adaptations in Muscle Strength, Function, Mass and Neuromuscular Function to a Pragmatic Home-based Resistance Exercise Intervention in Sedentary Older Adults: a Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sarcopenia
Keywords: Home exercise
Resistance exercise
Exercise
Krill oil
Muscle strength
Neuromuscular function
Physical function
Lead sponsor: University of Glasgow
Sponsor class: OTHER
First posted: 2023-05-22
Enrollment: 60
Sex: ALL
Minimum age (years): 60
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 1:1 parallel group design
Primary purpose: PREVENTION

Brief summary: The aim of this study is to determine whether krill oil supplementation enhances effects of a pragmatic resistance exercise programme on adaptations in muscle strength, mass, function and neuromuscular function in sedentary older adults. Hypothesis - krill oil supplementation will enhance the beneficial effects of resistance exercise on muscle strength, function, mass and neuromuscular function in sedentary older adults.


Eligibility criteria: Inclusion Criteria:

* Over the age of 60 years
* scoring a low level of physical activity based on international physical activity questionnaire (not meeting the recommend physical activity which is at least 600 MET-min per week).

Exclusion Criteria:

* Diabetes
* severe cardiovascular disease
* seizure disorders
* uncontrolled hypertension (\>150/90mmHg at baseline measurement)
* cancer or cancer that has been in remission \<5 years
* ambulatory impairments which would limit ability to perform assessments of muscle function
* dementia
* taking medication known to affect muscle (e.g. steroids)
* have an implanted electronic device (e.g. pacemaker/defibrillator/insulin pump)
* on anticoagulant therapy
* allergies to seafood
* regular consumption of more than 1 portion of oily fish per week
* already taking fish or krill oil or other n3 PUFA supplements
* femoral neck fracture or other severe of hip or knee operations
* stroke
* Parkinson's disease
* COPD
* kidney disease
* hyperlipidaemia
* obesity
* osteoporosis.

Primary outcomes:
measure: Nueromuscular Junction (NMJ) transmission instability
timeFrame: Change from baseline to 16 weeks
Secondary outcomes:
measure: Knee extensor maximal torque
timeFrame: Change from baseline to 8 16 weeks
measure: 30s chair stand test
timeFrame: Change from baseline to 16 weeks
measure: Gait speed
timeFrame: Change from baseline to 16 weeks
measure: Force steadiness during submaximal isometric knee extensor contractions
timeFrame: Change from baseline to 16 weeks
measure: Red Blood Cell Omega-3 levels
timeFrame: Change from baseline to 16 weeks
measure: Grip strength
timeFrame: Change from baseline to 16 weeks
measure: Muscle thickness
timeFrame: Change from baseline to 16 weeks
Other outcomes:
measure: Step Time (sec)
timeFrame: Change from baseline to 16 weeks
measure: Cycle Time (sec)
timeFrame: Change from baseline to 16 weeks
measure: Step Length (cm)
timeFrame: Change from baseline to16 weeks
measure: Stride Length (cm)
timeFrame: Change from baseline to16 weeks
measure: H-H Base Support (cm)
timeFrame: Change from baseline to 16 weeks
measure: Single Support (%GC)
timeFrame: Change from baseline to 16 weeks
measure: Double Support (%GC)
timeFrame: Change from baseline to 16 weeks
measure: Swing (%GC)
timeFrame: Change from baseline to 16 weeks
measure: Stance (%GC)
timeFrame: Change from baseline to 16 weeks
measure: Step/ Extremity Ratio
timeFrame: Change from baseline to 16 weeks
measure: Toe In / Out (deg)
timeFrame: Change from baseline to 16 weeks
measure: Distance (cm)
timeFrame: Change from baseline to 16 weeks
measure: Ambulation Time (sec)
timeFrame: Change from baseline to 16 weeks
measure: Velocity (cm/sec)
timeFrame: Change from baseline to 16 weeks
measure: Mean Normalized Velocity
timeFrame: Change from baseline to16 weeks
measure: Number of Steps
timeFrame: Change from baseline to 16 weeks
measure: Cadence (Steps/Min)
timeFrame: Change from baseline to 16 weeks
measure: Step Time Differential (sec)
timeFrame: Change from baseline to 16 weeks
measure: Step Length Differential (cm)
timeFrame: Change from baseline to 16 weeks
measure: Cycle Time Differential (sec)
timeFrame: Change from baseline to 16 weeks
Locations:
city: Glasgow
country: United Kingdom
facility: University of Glasgow
Study officials:
References: